The Association Between Hypertriglyceridemic-Waist Phenotype and Chronic Kidney Disease in Patients with Type 2 Diabetes: A Cross-Sectional METAL Study

Yan Xuan1,2,*, Wen Zhang1,*, Yuying Wang1, Bin Wang1, Yi Chen1, Fangzhen Xia1, Kun Zhang1, Qing Li1, Ningjian Wang1, Yingli Lu1

1Institute and Department of Endocrinology and Metabolism, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 2Department of Endocrinology, Luwan Branch, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200020, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Yingli Lu, Institute and Department of Endocrinology and Metabolism, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, People’s Republic of China, Tel +86-13636352507, Fax +86-21-63136856, Email luyingli2008@126.com

Background: The aim of this study was measuring the association between the hypertriglyceridemic-waist (HTGW) phenotype and chronic kidney disease in a large type 2 diabetes population.

Methods: A total of 4254 diabetic patients from the cross-sectional Environmental Pollutant Exposure and Metabolic Diseases in Shanghai (METAL) study were enrolled. The hypertriglyceridemic-waist (HTGW) phenotype was defined as the presence of an elevated waist circumference (WC) and elevated triglyceride (TG) concentration. Chronic kidney disease (CKD) was defined as an estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m^2 or urinary albumin creatinine ratio (uACR) more than 30 mg/g. Linear and multiple logistic regression models were used for measuring the association between HTGW phenotype and chronic kidney disease.

Results: The prevalence of CKD was 29% and 35.8% in total participants and participants with HTGW phenotype, respectively. Subjects in the HTGW phenotype group were more likely to have CKD (OR 1.47, 95% CI: 1.11, 1.95) compared with subjects in the normal waist circumference and normal triglycerides (NTNW) group. HTGW phenotype was both associated with the increasing risk of decreased eGFR (OR 1.31, 95% CI: 1.02, 1.75) and elevated uACR (OR 1.57, 95% CI: 1.18, 2.11). Furthermore, the stratified analysis showed that the strongest positive association between HTGW phenotype and CKD presence was found in the subgroup of presence of hypertension. The associations were all fully adjusted for age, sex, BMI, current smoking, current drinking and other confounding factors.

Conclusion: Our study suggested a positive association between the HTGW phenotype and CKD in Chinese type 2 diabetes patients. Further prospective studies are needed to confirm our findings and to investigate the underlying biological mechanisms.

Keywords: central obesity, type 2 diabetes mellitus, hypertriglyceridemia waist phenotype, chronic kidney disease

Introduction

Chronic kidney disease (CKD) has become a major public health concern worldwide for its increasing prevalence and devastating complications. Chronic kidney disease very likely goes to end-stage renal disease (ESRD) which needs renal replacement therapy for survival after losing about 90% of normal renal function. This situation increases the risk of cardiovascular disease (CVD) as well as mortality. Diabetes mellitus (DM) is the leading cause of ESRD, accounting for one-third of incident cases all over the world. Meanwhile, obesity increases the risk of CKD incidence and accelerates its progression to ESRD. The prevalence of obesity and diabetes has risen sharply, and they have been shown to be crucial risk factors for chronic kidney disease observed in China. Besides, the COVID-19 pandemic has refocused the adverse effects of obesity, diabetes and CKD on the general health status of individuals. There are growing
concerns that CKD patients with diabetes and obesity are more likely to suffer from severe mortality during the COVID-19 pandemic.8,9 Thus, it is important to control some novel metabolic risk factors contributing to chronic kidney disease in patients with type 2 diabetes mellitus (T2DM).10

The hypertriglyceridemic waist (HTGW) phenotype was first proposed in 2000, and defined as the presence of an elevated waist circumference, together with high levels of triglycerides (TGs).11 Waist circumference (WC), a classical marker of central obesity, is associated with increasing risk of CKD incidence.12 Some evidence suggested a link between high triglyceride levels and CKD incidence.13 The HTGW phenotype has advantages in assessing individuals with higher risk of metabolic abnormalities compared with elevated TG or enlarged WC used alone.14 Furthermore, several epidemiological studies showed the strong positive correlations of the HTGW phenotype with the risk of CVD,15,16 prediabetes and diabetes,17,18 hypertension,19,20 and hyperuricemia.21 Other studies reported the association of HTGW phenotype with an increasing risk of CKD in general middle-old adults22,23 and in lean people (BMI < 24 kg/m²).24 However, existing evidence on the association between HTGW and CKD remains controversial. Several studies found positive association between HTGW phenotype and CKD only in women,25,26 while another study of elderly participants came to an opposing conclusion.23 These studies were conducted in the general population, and few studies focused on diabetic patients with CKD. Meantime, studies assessing the association of HTGW phenotype with both decreased estimated glomerular filtration rate (eGFR) and elevated urine albumin/creatinine ratio (uACR) in T2DM population are rare. Therefore, our study aimed to prospectively explore the relationship of HTGW phenotype with chronic kidney disease in a large Chinese T2DM population.

**Materials and Methods**

**Study Population**

The cross-sectional Environmental Pollutant Exposure and Metabolic Diseases in Shanghai (METAL) study (www.chictr.org.cn, ChiCTR1800017573) was conducted in 2018 to investigate the relationship between diabetes complications and risk factors in Chinese diabetic patients. We enrolled participants from seven communities in the Huangpu and Pudong districts in Shanghai. In 2018, we obtained the list of diabetic patients who were Chinese citizens ≥18 years old and had lived in their current area for ≥6 months from the registration platform in each community healthcare center and then randomly selected 50% of them (n = 4937) to receive the examination by using SPSS Statistics, Version 22 (IBM Corporation, Armonk, NY, USA).27,28 In total, 4937 patients with diabetes were taken for examination. Those missing laboratory results (n = 267), questionnaire data (n = 116), HTGW phenotype data (n = 99), or CKD data (n = 201) were excluded. Finally, a total of 4254 participants were enrolled in the study (Figure 1). The study protocol was approved by the Ethics Committee of Shanghai Jiao Tong University School of Medicine affiliated to the Shanghai Ninth People’s Hospital.

The informed consent was obtained from all participants included in our study. The protocol followed the ethical guidelines of the 1975 Declaration of Helsinki, as reflected by the a priori approval granted by the appropriate institutional review committee.

**Clinical, Anthropometric and Laboratory Measurements**

A questionnaire about sociodemographic characteristics, medical history, family history, and lifestyle factors was adopted during the interview. The interviews and clinical examinations, including measurements of weight, height, and blood pressure, were conducted according to a standard protocol. They were taken by the same trained experienced personnel group involved in the Survey on Prevalence in East China for Metabolic Diseases and Risk Factors (SPECT-China).29,30 Body mass index (BMI) was calculated as weight (in kilograms) divided by height (in meters squared). Normal weight was defined as BMI < 24 kg/m², while overweight/obese was defined as BMI ≥24 kg/m² according to the Cooperative Meta-Analysis Group of the Working Group on Obesity in China criteria.31 Insulin resistance was evaluated using homeostasis model assessment of insulin resistance (HOMA-IR), which was calculated as the fasting glucose (mmol/L) × fasting insulin (mIU/L)/22.5.32 Blood pressure (BP) was measured by an electronic sphygmomanometer (Omron HEM-7200 Monitor, Batteries, and Stopwatch) and recorded by a trained physician. Before the BP measurement, the participants in this study were required to rest in a seated position for at least 5 minutes, and BP was measured 3 times at 5-minute intervals. The mean of the 3 readings was calculated. Waist circumference was measured 1 cm above
the umbilicus. Demographic information and lifestyle risk factors were gathered from standard questionnaires by trained staff. Drinking and smoking status were divided into never drinking/smoking and past or current drinking/smoking.

Blood samples were obtained after fasting for at least 8 h and were aliquoted and frozen at a central laboratory. Glycated hemoglobin (HbA1c) was measured by an automatic HbA1c analyzer (MEDCONN, Huizhong Medical Science and Technology Co., Ltd, Shanghai, China; Shanghai Huachen Biological Reagent Co., Ltd, Shanghai, China). Glutamic oxaloacetic transaminase (AST), glutamic pyruvic transaminase (ALT), fasting plasma glucose (FPG), total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL-C) and low-density lipoprotein cholesterol (LDL-C) were also measured (AU680 Chemistry Analyzer, Beckman Coulter, Brea, CA, USA). TG was measured with assay kits from Beckman Coulter (catalog number: AUZ5612, assay sensitivity: 0.01 mmol/L, intra-assay variability: 6.25%). The eGFR was determined using the Chinese modified Chronic Kidney Disease Epidemiology Collaboration. The concentrations of urine albumin and creatinine were measured with a Beckman Coulter AU 680 (Brea, CA, USA) using a turbidimetric immunoassay and an enzymatic method in a single spot urine sample respectively and uACR was calculated.

### Definition of Variables

Hypertension was diagnosed as systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or a self-reported previous physician’s diagnosis of hypertension. Chronic kidney disease was defined as an estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m² or urinary albumin creatinine ratio (uACR) ≥ 30 mg/g.34
Definitions of HTGW and the Rest of the Phenotypes

Central obesity was defined as a waist circumference $\geq 90$ cm in men and $\geq 80$ cm in women. The triglyceride level $\geq 1.7$ mmol/L was considered abnormal. Participants were grouped into four phenotype groups according to the measurements of TG and WC: (1) normal waist circumference and triglycerides (NWNT): TG $< 1.7$ mmol/L, WC $< 90$ cm for men and WC $< 80$ cm for women; (2) elevated triglycerides and normal waist circumference (NWET): TG $\geq 1.7$ mmol/L, WC $< 90$ cm for men and WC $< 80$ cm for women; (3) normal triglycerides and elevated waist circumference (EWNT): TG $< 1.7$ mmol/L, WC $\geq 90$ cm for men and $\geq 80$ cm for women; and (4) hypertriglyceridemic waist (HTGW): TG $\geq 1.7$ mmol/L, WC $\geq 90$ cm for men and $\geq 80$ cm for women.

Statistical Analyses

Data analyses were used by IBM SPSS version 22 statistical software (IBM Corp., Armonk, NY, USA). $P < 0.05$ indicated significance (two-sided). Continuous variables were expressed as the mean $\pm$ SD if the data were normally distributed or the median (interquartile range) if the data were not normally distributed, and categorical variables were expressed as percentages ($\%$). Linear and logistic regression analysis were carried out for the association of four phenotype groups and CKD presence. Because HOMA-IR values and uACR values were not normally distributed, we used a logarithmic transformation (base 10) to normalize the variables. Model 1 was adjusted for age, sex, BMI, current smoking and current drinking. Model 2 was adjusted for Model 1 plus AST, ALT, TC, LDL, FBG, HbA1c, UA, systolic blood pressure (SBP), diastolic blood pressure (DBP), anti-diabetes agents, hypertension and anti-hypertension agents.

For sensitivity analyses, we repeated the analyses to examine the association of triglyceride waist phenotypes and CKD presence. We performed stratified analyses by potential effect modifications: age ($<65$ years, $\geq 65$ years), sex, BMI ($<24$ kg/m$^2$, $\geq 24$ kg/m$^2$), HbA1c ($<7\%$, $\geq 7\%$), presence or absence of hypertension and the same confounding factors as adjusted for the analyses.

Since the cut-off values of high WC were different in several studies, we used another cut-off value (high WC was defined as $\geq 102.0$ for males and $\geq 88.0$ cm for females) to analyse the association between the HTGW phenotype and CKD presence in diabetes patients (data shown in Supplement Tables 1–4).

Results

Baseline Clinical Characteristics

Of the 4254 patients with type 2 diabetes, 2271 (53.4\%) were female, and the mean age was 66.6 (SD, 7.13) years. The baseline anthropometric parameters and biochemical indices according to four triglyceride waist phenotypes are shown in Table 1. Overall, participants in HTGW phenotype subgroup were older, had a higher proportion of female, worse life habits, were more likely to have a history of hypertension, overweight or obesity, CVD and poorer metabolic profiles including higher BMI, WC, blood pressure, lipids, FPG, HbA1c, UA and uACR and lower levels of HDL-C and eGFR ($P < 0.001$, Table 1). In Table 1, the prevalence of CKD was 29.3\% (1248/4254). In participants with HTGW phenotype, anti-diabetes medications were more prevalent ($P < 0.001$). Participants in HTGW group had the highest prevalence of CKD (531/1484 (35.8\%)) among the four subgroups ($P < 0.001$). Participants in NWET and EWNT groups had a higher prevalence of CKD (464/1661 (27.9\%), 93/319 (29.1\%), respectively) than those in NWNT group (160/790 (20.2\%)) ($P < 0.001$).

Under analysis by another cut-off value of high WC, the results did not significantly change (Supplementary Table 1).

Association Between HTGW Phenotypes and CKD

Table 2 shows that triglyceride waist phenotype was associated with CKD as well as decreased eGFR and elevated uACR. Compared with NWNT group, individuals with HTGW phenotype were associated with a higher risk of CKD.
Furthermore, HTGW phenotype was associated with the risk of decreased eGFR (OR 1.31, 95% CI: 1.02, 1.75) and elevated uACR (OR 1.57, 95% CI: 1.18, 2.11), respectively. What's more, further examined for another definition, there was no significant change in the results (Supplementary Table 2).

**Table 1** Characteristics of the Participants in Each Phenotype Group (n = 4254)

<table>
<thead>
<tr>
<th></th>
<th>NWNT</th>
<th>NWET</th>
<th>EWNT</th>
<th>HTGW</th>
<th>P for Trend</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of participants (%)</td>
<td>790(18.6)</td>
<td>1661(39.0)</td>
<td>319(7.5)</td>
<td>1484(34.9)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age at baseline (year)</td>
<td>66.13±8.83</td>
<td>67.33±9.03</td>
<td>64.89±9.29</td>
<td>66.41±8.85</td>
<td>0.192</td>
</tr>
<tr>
<td>Male (%)</td>
<td>541(68.5)</td>
<td>690(41.6)</td>
<td>193(60.5)</td>
<td>559(37.7)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>21.68±2.34</td>
<td>25.66±3.18</td>
<td>22.41±2.25</td>
<td>26.32±3.33</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>WC (cm)</td>
<td>79.38±6.41</td>
<td>92.68±8.07</td>
<td>80.56±6.05</td>
<td>94.02±8.37</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>138.32±20.13</td>
<td>144.40±19.43</td>
<td>141.99±19.53</td>
<td>146.37±19.28</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>76.81±10.62</td>
<td>78.40±10.72</td>
<td>79.40±10.54</td>
<td>81.00±10.54</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FBG (mmol/L)</td>
<td>6.95±2.26</td>
<td>7.15±2.18</td>
<td>7.27±2.40</td>
<td>7.81±2.69</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HbA1C (%)</td>
<td>7.00±1.43</td>
<td>7.15±1.31</td>
<td>7.16±1.47</td>
<td>7.41±1.44</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>1.53(1.03–2.24)</td>
<td>1.99(1.55–3.69)</td>
<td>2.38(1.39–6.24)</td>
<td>3.03(2.07–4.63)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>TG (mmol/L)</td>
<td>1.07±0.31</td>
<td>1.20±0.29</td>
<td>2.68±1.29</td>
<td>2.92±2.04</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>TC (mmol/L)</td>
<td>4.99±1.15</td>
<td>4.89±1.11</td>
<td>5.61±1.15</td>
<td>5.51±1.20</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HDL-C (mmol/L)</td>
<td>1.37±0.35</td>
<td>1.28±0.29</td>
<td>1.15±0.26</td>
<td>1.11±0.23</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LDL-C (mmol/L)</td>
<td>3.05±0.83</td>
<td>3.03±0.82</td>
<td>3.47±0.81</td>
<td>3.39±0.83</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>20.05±16.09</td>
<td>21.73±13.64</td>
<td>21.62±14.98</td>
<td>25.49±20.50</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>AST (U/L)</td>
<td>22.87±9.64</td>
<td>23.17±9.75</td>
<td>23.07±11.28</td>
<td>24.83±15.14</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>eGFR (mL/m/1.73 m²)</td>
<td>101.89±11.13</td>
<td>92.87±12.01</td>
<td>87.89±11.25</td>
<td>82.53±12.09</td>
<td>0.078</td>
</tr>
<tr>
<td>UACR (mg/dl)</td>
<td>10(6–19)</td>
<td>13(8–29)</td>
<td>14(7–28)</td>
<td>16(9–40)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>UA (μmol/L)</td>
<td>302.57±75.48</td>
<td>317.30±77.86</td>
<td>332.79±79.41</td>
<td>346.1±80.18</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CKD, (%)</td>
<td>160(20.2)</td>
<td>464(27.9)</td>
<td>93(29.1)</td>
<td>53(35.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Male (%)</td>
<td>114(71.3)</td>
<td>203(43.8)</td>
<td>56(60.2)</td>
<td>182(34.2)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>414(50.5)</td>
<td>1182(68.9)</td>
<td>196(58.2)</td>
<td>1148(74.5)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Overweight/obesity (%)</td>
<td>161(20.4)</td>
<td>1446(87.1)</td>
<td>95(29.9)</td>
<td>1381(93.1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Current smoking (%)</td>
<td>207(25.2)</td>
<td>225(13.1)</td>
<td>87(27.3)</td>
<td>261(17.6)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Current drinking (%)</td>
<td>163(20.7)</td>
<td>241(14.5)</td>
<td>58(18.4)</td>
<td>224(15.1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Treatment of diabetes</td>
<td>603(76.3)</td>
<td>1323(79.7)</td>
<td>236(70.0)</td>
<td>1208(81.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Oral-drug (%)</td>
<td>542(89.9)</td>
<td>119(90)</td>
<td>209(88.6)</td>
<td>1115(92.3)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Insulin (%)</td>
<td>119(19.7)</td>
<td>273(20.6)</td>
<td>41(17.3)</td>
<td>201(16.6)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Abbreviations: BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; HbA1c, glycosylated hemoglobin A1c; HOMA-IR, homeostasis model assessment of insulin resistance; TC, total cholesterol; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; ALT, alanine aminotransferase; AST, aspartate aminotransferase; UACR, urinary albumin–creatinine ratio; eGFR, estimated glomerular filtration rate; UA, uric acid; CKD, chronic kidney disease.

(OR 1.47, 95% CI: 1.11, 1.95) after adjusting for age, sex, BMI, current smoking, current drinking, AST, ALT, TC, LDL, HbA1c, FBG, UA, SBP, DBP, anti-diabetes agents, hypertension and anti-hypertension agents.

Furthermore, HTGW phenotype was associated with the risk of decreased eGFR (OR 1.31, 95% CI: 1.02, 1.75) and elevated uACR (OR 1.57, 95% CI: 1.18, 2.11), respectively. What's more, further examined for another definition, there was no significant change in the results (Supplementary Table 2).

**Association Between HTGW Phenotype and eGFR Level and uACR Level**

In Table 3, compared with the NWNT group, HTGW phenotype was significantly correlated with eGFR level ($\beta$ 0.07, 95% CI: -3.68, 1.39) and uACR level ($\beta$ 0.07, 95% CI: 0.09, 0.28) after adjusting for all confounders (all $P$ <0.001). These associations were all consistent between men and women (all $P$ <0.05). We further analyzed the association between the HTGW and CKD with the new definition in Supplementary Table 3 and did not significantly change the results.

**Association Between HTGW Phenotypes and CKD in Different Subgroups**

We further examined the association between triglyceride waist phenotypes and CKD in different subgroups of sex, age, BMI, HbA1c, and presence of hypertension in Table 4. The association between HTGW phenotype and
the risk of CKD remained consistent across almost all subgroups excluding the HbA1c <7% subgroup. The strongest positive association between HTGW phenotype and CKD was shown in the subgroup of presence of hypertension (OR 3.46, 95% CI: 1.56, 7.69). No significant interaction effect was observed between the triglyceride waist phenotypes and all subgroup variables in CKD risk and there was no significant change in results with the new definition, as shown in Supplementary Table 4.
### Table 4 Odds Ratios for CKD According to Triglyceride Waist Phenotypes by Various Subgroups

<table>
<thead>
<tr>
<th>Subpopulation</th>
<th>Cases/Participants</th>
<th>NWNT</th>
<th>NWET</th>
<th>EWNT</th>
<th>HTGW</th>
<th>P-Trend</th>
<th>P-Interaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;65</td>
<td>1938/4254</td>
<td>1.00 (ref)</td>
<td>1.18 (0.86,1.63)</td>
<td>1.71 (1.23,2.36)</td>
<td>1.43 (1.02,3.13)</td>
<td>&lt;0.001</td>
<td>0.542</td>
</tr>
<tr>
<td>≥65</td>
<td>2316/4254</td>
<td>1.00 (ref)</td>
<td>0.91 (0.75,1.12)</td>
<td>1.59 (1.28,1.99)</td>
<td>1.82 (1.01,3.10)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Gender&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>1983/4254</td>
<td>1.00 (ref)</td>
<td>1.06 (0.82,1.37)</td>
<td>1.72 (1.38,2.14)</td>
<td>1.31 (1.20,4.12)</td>
<td>&lt;0.001</td>
<td>0.678</td>
</tr>
<tr>
<td>Female</td>
<td>2271/4254</td>
<td>1.00 (ref)</td>
<td>1.04 (0.81,1.33)</td>
<td>1.27 (0.91,1.78)</td>
<td>1.44 (1.11,1.88)</td>
<td>0.008</td>
<td></td>
</tr>
<tr>
<td>BMI, kg/m&lt;sup&gt;2&lt;/sup&gt;&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 24</td>
<td>1403/4254</td>
<td>1.00 (ref)</td>
<td>1.57 (1.35,1.82)</td>
<td>1.73 (1.44,2.08)</td>
<td>2.13 (1.47,3.08)</td>
<td>&lt;0.001</td>
<td>0.784</td>
</tr>
<tr>
<td>≥ 24</td>
<td>2851/4254</td>
<td>1.00 (ref)</td>
<td>1.45 (0.86,2.45)</td>
<td>1.21 (0.54,2.72)</td>
<td>1.38 (1.01,2.85)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>HbA1c, %&lt;sup&gt;d&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;7</td>
<td>2581/4254</td>
<td>1.00 (ref)</td>
<td>1.04 (0.66,1.62)</td>
<td>1.23 (0.65,2.17)</td>
<td>1.53 (0.95,2.79)</td>
<td>0.078</td>
<td>0.458</td>
</tr>
<tr>
<td>≥7</td>
<td>1673/4254</td>
<td>1.00 (ref)</td>
<td>1.19 (0.73,1.96)</td>
<td>2.21 (1.31,3.76)</td>
<td>2.97 (1.58,5.56)</td>
<td>0.001</td>
<td></td>
</tr>
<tr>
<td>Presence of Hypertension&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>1430/4254</td>
<td>1.00 (ref)</td>
<td>1.64 (1.41,1.89)</td>
<td>1.94 (1.61,2.33)</td>
<td>1.32 (1.05,1.77)</td>
<td>&lt;0.001</td>
<td>0.262</td>
</tr>
<tr>
<td>Yes</td>
<td>2821/4254</td>
<td>1.00 (ref)</td>
<td>1.01 (0.60,1.72)</td>
<td>1.21 (0.31,2.72)</td>
<td>3.46 (1.56,7.69)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
</tbody>
</table>

Notes: For age subgroup: adjusted for sex, BMI, LDL-C, HDL-C, TC, FBG, HbA1c, UA, current smoking and current drinking, systolic blood pressure, diastolic blood pressure, anti-diabetes agents, hypertension, antihypertension drug. For gender subgroup: adjusted for age, BMI, LDL-C, HDL-C, TC, FBG, HbA1c, UA, smoking and current drinking, systolic blood pressure, diastolic blood pressure, anti-diabetes agents, anti-hypertension drug. For BMI subgroup: adjusted for age, sex, LDL-C, HDL-C, TC, FBG, HbA1c, UA, current smoking and current drinking, systolic blood pressure, diastolic blood pressure, anti-diabetes agents, hypertension, antihypertension drug. For HbA1c subgroup: adjusted for age, sex, BMI, LDL-C, HDL-C, TC, FBG, UA, current smoking, current drinking, systolic blood pressure, diastolic blood pressure, anti-diabetes agents, hypertension, anti-hypertension drug. For drink status subgroup: adjusted for age, sex, BMI, LDL-C, HDL-C, TC, FBG, HbA1c, UA, current smoking, current drinking, systolic blood pressure, diastolic blood pressure, anti-diabetes agents, antihypertension drug (only for hypertension group).

### Discussion

In this cross-sectional large population-based study, we explored the association between triglyceride waist phenotypes and the presence of CKD in a Chinese diabetes population. The major finding of the current study was that HTGW phenotype was a crucial risk factor of CKD presence compared with the other three phenotype groups for both sexes in the Chinese diabetes population. Subjects with HTGW phenotype were 1.67-fold more likely to have CKD than those in the NWNT group. The HTGW phenotype was correlated with decreased eGFR and elevated uACR. Furthermore, this positive relationship was independent of age, sex, BMI, history of hypertension, obesity, smoking status and drinking status.

Chronic kidney disease, asymptomatic in the early stage, carries a high risk of developing ESRD and has caused a huge medical burden all over the world. This is especially true in China due to swift changes in lifestyle and diabetes prevalence. Our study proves that the CKD prevalence in diabetes patients was 29.3%, with 51.2% in men and 48.8% in women, respectively, which is similar in previous studies. The prevalence of CKD in the four triglyceride waist phenotype groups were 20.2%, 27.9%, 29.1% and 35.8%, respectively. In diabetes patients, the number of deaths attributed to CKD with diabetes rose by 94%. Notably, most of the excess risk of CVD and all-cause mortality for patients with diabetes is related to the presence of CKD. In light of the huge social burden and strong correlation between CKD in T2DM patients and cardiovascular diseases, identifying high-risk asymptomatic individuals for CKD is of critical importance. Furthermore, our study explored that the distribution of triglyceride waist phenotype groups varied by gender. Women had a higher prevalence of HTGW and NWET phenotypes than men, probably due to the higher prevalence of central obesity and dyslipidemia in elderly women in China.

The present study provides evidence that eGFR in the HTGW group was 19 mL/m<sup>2</sup>/1.73 m<sup>2</sup> lower than that in the NTNW group. The uACR level was nearly twice as high in the HTGW group compared with the NTNW group (16 mg/g vs 10 mg/g). The participants in the HTGW group were 1.47-fold as likely to have CKD as those with NWNT, independent of age, sex and other potentially confounding factors. Our study further indicated that HTGW phenotype was correlated linearly with high uACR (OR 1.57, 95% CI: 1.18, 2.11) and decreased eGFR (OR 1.31, 95% CI: 1.02, 1.75). These findings were consistent with previous studies.
regardless of different ages, sex, participants with normal weight, non-current drinkers, individuals without DM, and those without hypertension, whereas HTNW was not significantly associated with incident CKD over a 4-year follow-up period.\textsuperscript{45} The possible explanations for the inconsistency across relevant studies might be the different study designs. First, our study used a cross-sectional analysis, unlike a study that applied longitudinal data. Second, we used a cut-off of 80 cm to define central obesity in women unlike most previous studies,\textsuperscript{21,26,46} which used 85 cm for women. But we also used other cut-off of high central obesity (high WC was defined as ≥102.0 for males and ≥88.0 cm for females) to analyse the association of HTGW with CKD. The results (in Supplement Tables 1–4) were consistent with our previous outcomes. Indeed, the association of HTGW with CKD is still insufficient to draw an accurate conclusion.\textsuperscript{22,26} Populations with different races and conditions may explain partly the inconsistency and more studies are required to further explore this association. On the other hand, participants with the HTGW phenotype simultaneously had elevated glucose (FBG, 7.81 mmol/l vs 6.95 mmol/l) and poor glucose control (HBA1c, 7.41% vs 7%) compared with those in the NTNW group. We further found a higher prevalence of obesity and hypertension in the HTGW phenotype group than in the NTNW group (93.1% vs 20.4%, 74.5% vs 50.5%, respectively). According to these results, the insulin resistance is more serious in participants with the HTGW phenotype than those in the NTNW group (HOMA-IR, 3.03 vs 1.53). IR has been confirmed to be strongly associated with a failure of renal function.\textsuperscript{47} Although some potential mechanisms for the association between IR and CKD remain unclear, the potential mechanisms such as uremic toxin retention, glucose dysregulation, inflammation, acidosis, adiposity, abnormal mineral metabolism and hypertension have been implicated.\textsuperscript{48} Apart from that evidence has suggested that visceral adiposity, rather than subcutaneous adiposity, was more closely related to metabolic abnormalities, such as insulin resistance, hypertension, and dyslipidemia,\textsuperscript{49} which were all well-established risk factors of CKD.\textsuperscript{50} The other probable mechanism of this phenomenon was the association between obesity and fatty kidney disease. The term “fatty kidney”, first named in the literature in 1883,\textsuperscript{51} suggests that hyperlipidemia is the cause of renal lipid accumulation and nephrotoxicity.\textsuperscript{52} Obesity is correlated with initial hyperfiltration leading to elevated renal tubular sodium reabsorption and a subsequent gradual decline in the estimated glomerular filtration rate.\textsuperscript{53} Adipocytes are linked to secrete all components of the RAAS and are upregulated in obesity.\textsuperscript{53} Therefore, the kidney is not just a victim but rather an active co-conspirator in metabolic syndrome.

The HTGW phenotype has also been widely accepted in risk assessment or prediction of high visceral fat,\textsuperscript{14} metabolic syndrome,\textsuperscript{54} and fatty liver.\textsuperscript{55} All these results support that the HTGW phenotype is a cost-effective screening tool that can be used in clinical practice and an efficient and effective phenotype that can be used in health management.

We further used stratified analyses, the positive association between HTGW phenotype and CKD risk still persisted across almost all subgroups; The strongest association of HTGW phenotype with CKD risk was found in the subgroup of hypertension, indicating the predictive power of HTGW phenotype for CKD might be better for diabetes patients with hypertension. Consistent with other studies, hypertension was the obvious risk factor of CKD in diabetes patients.\textsuperscript{56}

This study included several limitations that need to be considered. First, this is a study of cross-sectional design. It is unable to assess the temporal and causal relationship. Further prospective studies should be designed to test potential mechanisms and these results. Second, many confounding factors such as diet and family history of CKD still may exist, although multiple confounders were adjusted. Third, since the study is not nationally representative, the results obtained need to be carefully summarized. Further studies with a large number of general participants or randomized controlled trials are still required.

**Conclusions**

In conclusion, a significant positive association of HTGW phenotype with CKD was observed in a Chinese diabetes population. Individuals with T2DM with HTGW were at higher risk to face CKD than those with NWNT. In addition, more research should be carried out to focus on the waist circumference and TG level in clinical screening and intervention. Finally, further large-scale prospective studies for the other potential mechanisms are still essential to conduct.
**Data Sharing Statement**
The raw data used in the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher. Yingli Lu could be contacted to provide that data.

**Informed Consent Statement**
Informed consent was obtained from all subjects involved in the study.

**Acknowledgments**
The authors thank all team members and participants in the METAL study.

**Author Contributions**
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

**Funding**
This study was supported by National Natural Science Foundation of China (91857117); Science and Technology Commission of Shanghai Municipality (18410722300, 19140902400, 20015800400, 20ZR1432500); the Major Science and Technology Innovation Program of Shanghai Municipal Education Commission (2018YFC1705103); Shanghai Municipal Human Resources and Social Security Bureau (2020074); Clinical Research Plan of SHDC (SHDC2020CRY006); Shanghai Municipal Huangpu District Commission (HLQ202004). The funders played no role in the design or conduct of the study, interpretation, analysis, collection, or management of data or in the review, preparation or approval of the article.

**Disclosure**
The authors in this study declare no conflicts of interest.

**References**


